AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting

AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026.

Approved setting

Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase-inhibitor plus CDK4/6-inhibitor treatment, using an FDA-authorised test.

This is a specific molecularly selected treatment setting, rather than approval for all breast cancers.

Supporting evidence

In SERENA-6, median progression-free survival was 16.0 versus 9.2 months, with a hazard ratio of 0.44. The reported 56% reduction concerns the relative hazard of progression or death; it is not a 56-percentage-point survival improvement.

A subsequent analysis showed a second-progression endpoint benefit. Overall-survival evidence remains immature, and the trial continues to assess it. The company reports no new safety concerns in the trial.

Commercial implications

Approval creates a US treatment opportunity, while uptake depends on mutation testing, clinical adoption and access. Today's release does not quantify incremental sales.

The next evidence includes commercial availability, utilisation and continued clinical follow-up under the accelerated-approval pathway.

Source: Company announcement, 7 September 2026.